Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 13,780,000 shares, an increase of 33.3% from the April 30th total of 10,340,000 shares. Approximately 34.4% of the shares of the stock are short sold. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is presently 6.7 days.

Analyst Ratings Changes

Several research firms have recently issued reports on CAPR. Roth Capital started coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $31.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. raised its holdings in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 1,345 shares during the last quarter. Krilogy Financial LLC lifted its position in Capricor Therapeutics by 9.6% during the first quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company's stock worth $216,000 after acquiring an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Capricor Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company's stock worth $1,079,000 after purchasing an additional 2,314 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock valued at $203,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock traded up $0.94 during midday trading on Tuesday, hitting $11.15. The company had a trading volume of 2,062,255 shares, compared to its average volume of 1,748,395. The stock has a market cap of $509.30 million, a PE ratio of -10.52 and a beta of 0.85. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business's 50 day simple moving average is $10.15 and its two-hundred day simple moving average is $13.05.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. During the same quarter in the prior year, the firm posted ($0.31) earnings per share. On average, sell-side analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.